Literature DB >> 24801468

Barriers to self-administered therapy for hereditary angioedema.

Linh-An C Tuong1, Kirsten Olivieri, Timothy J Craig.   

Abstract

Presently, the movement of care for hereditary angioedema (HAE) is out of the clinic, emergency department, and hospitals and into the home. Much of the transition relies on specialized nurses who teach patients self-administration skills. Our goal was to assess nurses to uncover barriers that they have encountered in an effort to improve self-therapy education and patient care. A survey of 21 questions was sent to 38 HAE home care nurses throughout the United States. Results were collected anonymously and data were analyzed. Nurses feel that there is an increased need for teaching patients self-therapy skills. The majority are very comfortable teaching self-administration and troubleshooting-associated problems. Perceived difficulties in providing adequate teaching include distance to patient's home and logistics of coordinating, scheduling, and obtaining supplies. Teaching is preferred when done at home by a visiting nurse with a care partner available and multiple training sessions are needed. Very few patients refused self-administration after initially being taught; reasons cited for refusal include fear of injection or infection, lack of skills, interference of daily activities, and financial restraints. As for nurses, they were most worried about safety, lack of skill retention, and inappropriate use of the drug. Self- administration of HAE treatment is increasingly more accessible and should be offered to patients as a safe and practical option. The barriers to self-administration revealed in this study include distance to the patient's home, coordinating care, obtaining medications/equipment, and scheduling training sessions. Moving to self- or home treatment through nursing instruction will improve patient's independence and quality of life, lead to earlier therapy, and reduce costs associated with care.

Entities:  

Mesh:

Year:  2014        PMID: 24801468     DOI: 10.2500/aap.2014.35.3753

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  12 in total

1.  Insights, strategies, asthma and allergy risk factors, and the allergist/immunologist: Challenges to be met and promises to keep!

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2016 Jan-Feb       Impact factor: 2.587

2.  Disorders for which the allergist-immunologist is particularly well-qualified to treat.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

3.  Wheels within wheals: the burden of urticaria and angioedema.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 Mar-Apr       Impact factor: 2.587

4.  United airway disease.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2014 Sep-Oct       Impact factor: 2.587

5.  Quality of life issues ranging from the burden of ocular and nasal allergies to the anxiety associated with having to carry self-injectable epinephrine for insect sting allergy.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2014 May-Jun       Impact factor: 2.587

6.  The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Authors:  Marcus Maurer; Markus Magerl; Stephen Betschel; Werner Aberer; Ignacio J Ansotegui; Emel Aygören-Pürsün; Aleena Banerji; Noémi-Anna Bara; Isabelle Boccon-Gibod; Konrad Bork; Laurence Bouillet; Henrik Balle Boysen; Nicholas Brodszki; Paula J Busse; Anette Bygum; Teresa Caballero; Mauro Cancian; Anthony J Castaldo; Danny M Cohn; Dorottya Csuka; Henriette Farkas; Mark Gompels; Richard Gower; Anete S Grumach; Guillermo Guidos-Fogelbach; Michihiro Hide; Hye-Ryun Kang; Allen P Kaplan; Constance H Katelaris; Sorena Kiani-Alikhan; Wei-Te Lei; Richard F Lockey; Hilary Longhurst; William Lumry; Andrew MacGinnitie; Alejandro Malbran; Inmaculada Martinez Saguer; Juan José Matta Campos; Alexander Nast; Dinh Nguyen; Sandra A Nieto-Martinez; Ruby Pawankar; Jonathan Peter; Grzegorz Porebski; Nieves Prior; Avner Reshef; Marc Riedl; Bruce Ritchie; Farrukh Rafique Sheikh; William B Smith; Peter J Spaeth; Marcin Stobiecki; Elias Toubi; Lilian Agnes Varga; Karsten Weller; Andrea Zanichelli; Yuxiang Zhi; Bruce Zuraw; Timothy Craig
Journal:  World Allergy Organ J       Date:  2022-04-07       Impact factor: 5.516

7.  Hereditary angioedema patients would prefer newer-generation oral prophylaxis.

Authors:  Daniela Geba; Johan Mohd Sani; Michaela Gascon; Rebecca Hahn; Kavita Aggarwal; Jinky Rosselli
Journal:  J Drug Assess       Date:  2021-01-06

8.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.

Authors:  Veronica Squeglia; Alessandro Barbarino; Maria Bova; Carmela Gravante; Angelica Petraroli; Giuseppe Spadaro; Massimo Triggiani; Arturo Genovese; Gianni Marone
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

9.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.

Authors:  H Farkas; I Martinez-Saguer; K Bork; T Bowen; T Craig; M Frank; A E Germenis; A S Grumach; A Luczay; L Varga; A Zanichelli
Journal:  Allergy       Date:  2016-09-08       Impact factor: 13.146

10.  Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.

Authors:  Andrea Zanichelli; Giulia Maria Azin; Federico Cristina; Romualdo Vacchini; Teresa Caballero
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.